Vistagen Therapeutics Inc  

(Public, OTCMKTS:VSTA)   Watch this stock  
Find more results for otc:vsta
-0.010 (-1.64%)
Delayed:   12:04PM EDT
OTCMKTS data delayed by 15 mins - Disclaimer
Currency in USD
Range 0.50 - 0.60
52 week 0.25 - 0.89
Open 0.50
Vol / Avg. 2,700.00/1,953.00
Mkt cap 15.27M
P/E     -
Div/yield     -
EPS -0.24
Shares 25.45M
Beta -258.62
Inst. own 3%

Key stats and ratios

Q1 (Mar '14) 2014
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -2469.95% -518.28%
Return on average equity - -
Employees 10 -
CDP Score - -


United States - Map
+1-650-5773600 (Phone)

Website links


VistaGen Therapeutics, Inc. (Vistagen) is a biotechnology company. The Company is engaged in the human pluripotent stem cell technology (hPSC technology). The Company is applying its hPSC technology for drug rescue, predictive toxicology and drug metabolism screening. The Company´┐Żs products include CardioSafe 3D, LiverSafe 3D and AV-101. The Company has developed CardioSafe 3D, a three-dimensional (3D) in vitro bioassay system for predicting in vivo cardiac effects, both toxic and non-toxic, of small molecule drug candidates long before they are tested in animals or humans. With its mature human liver cells derived from pluripotent stem cells, the Company is developing and validating LiverSafe 3D, a three-dimensional (3D) in vitro bioassay system for assessing liver toxicity and drug metabolism issues. AV-101 is its orally available small molecule prodrug candidate aimed at the multi-billion dollar neurological disease and disorders market.

Officers and directors

H Ralph Snodgrass Ph.D. President, Chief Scientific Officer, Director
Age: 63
Shawn K. Singh J.D. Chief Executive Officer, Director
Age: 50
Jerrold D. Dotson CPA Chief Financial Officer
Jon S. Saxe Independent Director
Age: 77
Brian J. Underdown Ph.D. Independent Director
Age: 72